<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">BASALIT-trial: Double blind placebo controlled allergen immunotherapy with rBet v 1-FV in birch related soy allergy</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Regina</forename><forename type="middle">;</forename><surname>Treudler</surname></persName>
							<email>regina.treudler@uniklinik-leipzig.de</email>
							<affiliation key="aff2">
								<orgName type="department">Dept. of Dermatology, Venerology and Allergology</orgName>
								<orgName type="institution">Universität Leipzig</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annegret</forename><forename type="middle">;</forename><surname>Franke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anett</forename><forename type="middle">;</forename><surname>Schmiedeknecht</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Barbara</forename><surname>Ballmer-Weber</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Franke</forename><surname>Annegret</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Clinical Trial Centre Leipzig (ZKS)</orgName>
								<orgName type="institution">Universität Leipzig</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Schmiedeknecht</forename><surname>Anett</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Clinical Trial Centre Leipzig (ZKS)</orgName>
								<orgName type="institution">Universität Leipzig</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ballmer-Weber</forename><surname>Barbara</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Centre of Dermatology and Allergology</orgName>
								<orgName type="laboratory">Allergy Unit</orgName>
								<orgName type="institution" key="instit1">University Hospital Zürich</orgName>
								<orgName type="institution" key="instit2">Luzerner Kantonsspital</orgName>
								<address>
									<settlement>Luzern</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Worm</forename><surname>Margitta</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Dermatology, Venerology and Allergology</orgName>
								<orgName type="laboratory">Allergy Center Charité</orgName>
								<orgName type="institution">Charité</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Werfel</forename><surname>Thomas</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Dermatology and Allergology</orgName>
								<address>
									<settlement>Hannover</settlement>
									<region>MH</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jappe</forename><surname>Uta</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Division of Clinical &amp; Molecular Allergology Research Center Borstel</orgName>
								<orgName type="institution">Airway Research Center North</orgName>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Dept. of Internal Medicine</orgName>
								<orgName type="laboratory">Interdisciplinary Allergy Outpatient Clinic</orgName>
								<orgName type="institution">University of Lübeck</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Biedermann</forename><surname>Tilo</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Universität Tübingen</orgName>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Dermatology and Allergology</orgName>
								<orgName type="department" key="dep2">Dept. of Dermatology</orgName>
								<orgName type="department" key="dep3">Medical Faculty Carl Gustav Carus</orgName>
								<orgName type="institution">Technical University Munich 10</orgName>
								<address>
									<country>TU Dresden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Schmitt</forename><surname>Jochen</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Center for Evidence-based Healthcare</orgName>
								<orgName type="department" key="dep2">Medical Faculty Carl Gustav Carus</orgName>
								<address>
									<country>TU Dresden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brehler</forename><surname>Randolf</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Universität Münster</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kleinheinz</forename><surname>Andreas</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Dermatology</orgName>
								<address>
									<settlement>Elbekliniken Buxtehude 14 Allergy-and asthma centre Westend, Berlin</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kleine-Tebbe</forename><surname>Jörg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Brüning</forename><surname>Harald</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ruëff</forename><surname>Franziska</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Dermatology and Allergology</orgName>
								<orgName type="institution">Ludwig-Maximilian University</orgName>
								<address>
									<settlement>Munich</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ring</forename><surname>Johannes</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Dermatology and Allergology</orgName>
								<orgName type="department" key="dep2">Dept. of Dermatology</orgName>
								<orgName type="department" key="dep3">Medical Faculty Carl Gustav Carus</orgName>
								<orgName type="institution">Technical University Munich 10</orgName>
								<address>
									<country>TU Dresden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Saloga</forename><surname>Joachim</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">University Medical Center</orgName>
								<orgName type="institution" key="instit2">Johannes Gutenberg-University</orgName>
								<address>
									<settlement>Mainz</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Schäkel</forename><surname>Knut</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution" key="instit1">Ruprecht-Karls-Universität Heidelberg 19 Division of Allergology</orgName>
								<orgName type="institution" key="instit2">Paul-Ehrlich-Institut</orgName>
								<address>
									<settlement>Langen</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Holzhauser</forename><surname>Thomas</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Vieths</forename><surname>Stefan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><surname>Jan</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Dept. of Dermatology, Venerology and Allergology</orgName>
								<orgName type="institution">Universität Leipzig</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Universitätsmedizin</forename><surname>Berlin</surname></persName>
						</author>
						<author>
							<persName><roleName>Prof. Dr. med</roleName><forename type="middle">Regina</forename><surname>Treudler</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Zurich Open Repository</orgName>
								<orgName type="institution">Archive University of Zurich Main Library Strickhofstrasse 39</orgName>
								<address>
									<postCode>CH-8057</postCode>
									<settlement>Zurich www.zora.uzh.ch</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Zurich Open Repository and Archive</orgName>
								<orgName type="institution">University of Zurich ZORA URL</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Dermatology, Venerology and Allergology</orgName>
								<orgName type="laboratory">Leipziger Interdisziplinäres Centrum für Allergologie (LICA) -Comprehensive Allergy Centre</orgName>
								<orgName type="institution">Universität Leipzig Philipp-Rosenthal-Straße</orgName>
								<address>
									<postCode>23 04103</postCode>
									<settlement>Leipzig</settlement>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">BASALIT-trial: Double blind placebo controlled allergen immunotherapy with rBet v 1-FV in birch related soy allergy</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">0F32325B7BC55B99FE1C9245E356386F</idno>
					<idno type="DOI">10.1111/all.13112</idno>
					<note type="submission">This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/all.13112 Received Date : 06-Apr-2016 Revised Date : 14-Nov-2016 Accepted Date : 17-Dec-2016 Article type : Original Article: Gastrointestinal Diseases</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Birch food allergy</term>
					<term>soy</term>
					<term>allergen specific immunotherapy</term>
					<term>recombinant Bet v1</term>
					<term>molecular</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The clinical trial BASALIT (Birch Associated Soy Allergy and Immuno-Therapy) was funded by the German Federal Ministry of Education and Research (FK 01KG0911).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Sensitization to major birch pollen allergen Bet v 1 is often associated with pollen related food allergy (FA) <ref type="bibr" target="#b0">[1]</ref> and birch related soy allergy became of growing importance during the last years <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>.</s><s>The immunologic basis for birch pollen related FA results from IgE antibodies (ab) that are raised against major pollen allergens but that can also recognize homologous allergens belonging to the pathogenesis-related protein family 10, for example Gly m 4 in soybean <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>.</s></p><p><s>There is still controversy as to whether pollen related FA can be successfully treated with allergen immunotherapy (AIT) with pollen allergens <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s><s>As birch pollen AIT was shown to induce Bet v 1 specific (s) IgG4-ab that cross react with related food allergens and inhibit IgE binding by epitope competition, clinical effects of AIT on pollen related FA are to be expected <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b11">12]</ref>.</s><s>Within previous investigations, birch pollen AIT with either sublingual (SLIT) or subcutaneous (SCIT) application, improved pollen related FA in some studies <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref> while others could not confirm this <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref>.</s><s>The studies that reported improvement <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref> were not placebo-controlled and did not include DBPCFC for endpoint assessment.</s><s>The only existing randomized placebo-controlled trial investigated clinical effects of birch pollen AIT (single maximum dose 12.3µg Bet v 1/ml <ref type="bibr" target="#b20">[21]</ref>) on birch related hazelnut FA by DBPCFC and was not able to detect group differences <ref type="bibr" target="#b18">[19]</ref>.</s><s>It was suggested, that doses to induce an appreciable effect of birch pollen AIT on pollen related FA should be higher than those sufficient to improve pollen related respiratory symptoms <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b20">21]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p><p><s>Because of the growing number of affected patients and increasingly frequent reports on severe reactions <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b5">6]</ref>, we decided to investigate the effect of rBet v 1-FV AIT (single maximum dose 80µg/ml of Bet v 1/ml <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>) on birch related soy FA.</s><s>The multicentric setting required previous standardization of DBPCFC with soy <ref type="bibr" target="#b23">[24]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Setting and patient selection</head><p><s>Between 1/2010 and 2/2013, 195 adults (18 -65 years) with history of birch pollen allergy were recruited in 16 centres (15 German, one Swiss).</s><s>They underwent standardized allergy interview, skin prick test (SPT) as well as serum IgE test (see fig. <ref type="figure">1</ref>).</s><s>We defined eligibility for DBPCFC if patients had positive SPT for birch, ≥ 3.5kU/l of sIgE for birch allergen Bet v 1 and ≥ 0.7kU/l for its soy homologue Gly m 4 (ThermoFisher, Freiburg, Germany).</s><s>The trial (EudraCT-Nr.: 2009-011737-27) was approved by the competent authorities in Germany and Switzerland; the leading ethic committee was located at University Medical Centre Leipzig (UMCL).</s><s>All patients provided written informed consent.</s><s>Main exclusion criteria were pregnancy and unstable asthma.</s><s>The following drugs were contraindicated during AIT: Ongoing immunosuppression, long-term treatment with tranquilizers/psycho active drugs, betablocker, ongoing/previous anti-IgE therapy.</s><s>The following drugs were allowed if needed: antihistamines, topical glucocorticosteroids, systemic glucocorticosteroids up to 7.5mg prednisolone equivalent ≤ 5 days.</s><s>A sample size of 97 subjects (with randomization ratio 2:1) was regarded sufficient to reach a study power of ≥ 90%, based on lowest observed adverse effect levels for objective signs (LOAEL obj ) and subjective symptoms (LOAEL subj ) as two primary endpoints without hierarchy.</s><s>LOAELs (including their heterogeneity) as presented previously <ref type="bibr" target="#b3">[4]</ref> were used for calculation of sample size, as well as clinically relevant group differences of 20g in LOAEL obj , 10g in LOAEL subj and 15% non-compliance/drop-out rate.</s><s>NCSS/ PASS software was applied.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Skin prick test</head><p><s>At baseline, SPT was performed with commercially available supplement free soy drinks (single prick to prick test, ALPRO, Uelzena, Germany) and with a panel of respiratory allergens including birch (Allergopharma GmbH &amp; Co KG, Reinbek, Germany) for inclusion (cutoff &gt;/=3mm).</s><s>Due to unexpected market withdrawal of the drink planned to be applied, only in case of comparable drinks used both before and following AIT, any reduction of wheal diameter at the end of treatment (as binary outcome) was analysed.</s><s>Also, circle-approximated soy induced wheal area was divided by that induced by histamine (histamine adjusted soy reaction/HASR) in analogy to Dreborg <ref type="bibr" target="#b24">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Double blind placebo controlled food challenge</head><p><s>Standardization of DBPCFC including composition of CM with consistent Gly m 4 levels was previously described <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>Single dose levels of soy protein were 0.0004 -0.0044 -0.05 -0.15 -0.5 -1.5 -2.5 -5 -15g with a maximum cumulative dose of 24.7g protein.</s><s>Investigators monitored 10 objective signs and patients recorded 8 subjective symptoms on 10cm visual analogue scales (VAS) each.</s></p><p><s>DBPCFC was stopped after dose level 9 or if the patient showed any objective symptoms before.</s></p><p><s>DBPCFC was defined positive if a patient presented at least one of the following reactions: &gt;/=1 objective sign and/or &gt;/=1 subjective symptoms (VAS value reaching 1.5cm or more and/or two or more subjective symptoms with single VAS values each reaching 0.5cm or more and summing up to 4cm or more in total) <ref type="bibr" target="#b23">[24]</ref>.</s></p><p><s>LOAELs corresponding to minimal reactive/threshold dose for objective signs and subjective symptoms were determined.</s><s>In order to be able to detect any post interventional increase in symptom eliciting doses, we only included patients for AIT in whom DBPCFC was judged as positive at dose level 7 (single dose 2.5g, cumulative 4.7g soy protein) or below.</s><s>Post interventional DBPCFC was performed within three months after end of AIT.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory investigations</head><p><s>sIgE-and sIgG4-ab were determined by using ImmunoCAP (Thermo Fisher Scientific, Freiburg, Germany).</s><s>At screening, sIgE-ab against Bet v 1 and Gly m 4 were measured for inclusion.</s><s>sIgE-and sIgG4-ab [27] against birch allergens Bet v 1, Bet v 2, soy extract, the soy allergens Gly m 4, Gly m 5, Gly m 6, frequent birch related food allergens Api g 1 (celery), Cor a 1 (hazelnut), Dau c 1 (carrot; made of equimolar ratio of Dau c 1.0104 and Dau c 1.0201), Mal d 1 (apple) and Pru av 1 (cherry) as well as sIgE against cross reacting carbohydrate determinants (MUXF3) were investigated at different time (t) points: t1 -at first injection, t2 -at end of up dosing, t3 at start of maintenance therapy, t4 at fourth dose, and t5 at last injection.</s><s>Blood samples of all randomized subjects were shipped to Paul-Ehrlich-Institut, Langen, Germany, and stored at -80°C until assayed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Investigational medical product and therapy</head><p><s>The recombinant hypoallergenic derivative of the major birch pollen allergen rBet v 1-FV as well as the comparative placebo compound (both containing aluminium hydroxide, phenol, sodium chloride, sodium hydrogen carbonate) were manufactured by Allergopharma GmbH &amp; Co. KG (Reinbek, Germany) <ref type="bibr" target="#b21">[22]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients were randomized to either active (rBet v 1-FV) or placebo intervention. Up-dosing of patients</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p><p><s>started in 2010, 2011 or 2012 between July and October.</s><s>The starting dose (strength A) was 0.75µg (0.15ml), continued with increasing dosages of 1.5/3.0/5µg</s><s>(0.3/0.6/1.0ml) and then of 10/20/40/80µg (0.1/0.2/0.4/0.8 ml of strength B).</s><s>During up-dosing injections were administered at one weekly interval, with a maximum single dose of 80 µg.</s><s>During prolongation, there were gradually increased injection intervals from 7-28 days.</s><s>During maintenance, injections were applied every 28 days with a 50% reduction during the birch pollen season.</s><s>Asthma patients were monitored with peak flow at each trial injection.</s><s>Patients of per protocol set population (PPP) had received a cumulative dose of at least 150µg major allergen (or placebo equivalent).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome measures</head><p><s>Primary endpoints were DBPCFC-based LOAELs LOAEL obj and LOAEL subj .</s><s>Additionally, occurrence of any objective signs or subjective symptoms at post interventional DBPCFC was investigated.</s></p><p><s>Secondary endpoints were (i) courses of sIgE-and sIgG4-ab levels for Bet v 1, Gly m 4 and other birch related foods from baseline to end of treatment, (ii) pre-post changes of reactivity at SPT (if suitable) as well as (iii) pre-post changes of FA related quality of life (QoL) via FA quality of life questionnaireadult form (FAQLQ-AF) <ref type="bibr">[28,</ref><ref type="bibr">29]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p><s>The confirmatory analysis was based on the full analysis set (FAS) with baseline LOAEL instead of missing values at end of study if applicable and intention-to-treat principle.</s><s>We focused on two primary endpoints without hierarchy -both LOAEL obj and LOAEL subj since it was unclear in advance how many patients would react with objective signs at DBPCFC.</s><s>Post-interventional measures after the ingestion of soy-containing CM were used in nonparametric analysis of covariance (ANCOVA) with corresponding baseline measures as covariates <ref type="bibr">[30]</ref>.</s><s>The global significance level of the clinical trial was limited to α=5%.</s><s>The test-wise α-levels were adjusted for multiplicity according to the Bonferroni-Holm method [31] based on the ordered p values observed.</s><s>The smaller observed p-values p(1) (corresponding with either LOAEL obj or LOAEL subj ) had to be lower than/equal to α(1)=α global /2=0.025≥p(1) to identify a significant treatment effect in at least one LOAEL.</s><s>For the 2 nd comparison p(2)≤α(2)=0.05</s><s>should be observed to establish significance in both endpoints.</s><s>SAS macros developed and provided by the University of Göttingen within the German Research Foundation (DFG) sponsored project "Ordinal Data" were used to compare the treatments without any further covariates in confirmatory analysis.</s><s>In a planned sensitivity analysis, the same procedures as in confirmatory analysis were applied within the per protocol population (PPP).</s><s>Secondary and safety outcomes were analyzed by Fishers exact test, repeated-measures ANCOVA, and Mann-Whitney U test, with neither adjustment for multiplicity nor missing value imputations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristics of screening and study population</head><p><s>195 patients (63.4% female, mean (SD) of age 38.1(12.8))</s><s>years were screened.</s><s>138 patients were eligible for DBPCFC, 82 (59.4%) had positive DBPCFC at baseline <ref type="bibr" target="#b23">[24]</ref>.</s><s>Out of those 82, 56 patients were randomized (2:1) to interventional AIT with rBet v 1-FV (n=38) or placebo (n=18) (figure <ref type="figure">1</ref>).</s></p><p><s>19/38 (50%) and 8/18 (44%) had a history of previous reactions to any soy product.</s><s>13/38 (34%) and 8/18 (44%) underwent a previous AIT.</s><s>Table <ref type="table" target="#tab_2">1</ref> contains major characteristics of the trial population.</s><s>54/56 randomised patients started the intervention, meaning that only 56% (54/97) of the intended sample size could be recruited within the given time frame.</s><s>Major protocol violations occurred in 9/54 subjects: in the active group, two subjects did not fulfil criteria for positive DBPCFC and in three other cumulative AIT allergen doses applied were below 150µg.</s><s>In four subjects of active and two from placebo group no post interventional DBPCFC was performed.</s><s>PPP included 45 subjects (for details see table <ref type="table" target="#tab_2">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Allergen immunotherapy and adverse events</head><p><s>Maintenance phase was reached in 31/37 (84%) patients of active and in 16/17 (94%) of placebo group.</s><s>Cumulative allergen doses are given in table 1.</s><s>During treatment course, 119 injection related adverse events (AE) occurred in 22/37 (60%) patients of the active and in 9/17 (53%) of the placebo group.</s><s>AEs were almost exclusively mild: 64/119 (54%), consisted in localized injection site reactions, 13/119 (11%) were skin reactions with generalized urticaria in one subject, 15/119 (13%) had respiratory (nose/lung; 3 asthmatic responses in 2 patients), 7/119 (6%) eye and 20/119 (17%) unspecific symptoms.</s><s>There were no injection related serious AEs.</s><s>During AIT, systemic intake of antihistamines was documented in 21/54 (39%) and of short-term systemic glucocorticosteroids in 8/54 (15%) subjects (due to skin lesions in n=6 or asthma in n=2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Double blind placebo controlled food challenges</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p><p><s>LOAELs, type of objective signs or type of subjective symptoms.</s></p><p><s>In confirmatory analyses, in PPP (but not in FAS), LOAEL obj tended to be higher in the active group (treated with rBet v 1-FV) compared with the placebo group (p=0.081).</s><s>Individual dose level changes are shown in figure <ref type="figure">3</ref>.</s><s>With the best/worst case groups-related observations (regarding betweengroup differences, heterogeneity and LOAEL obj as exclusive primary endpoint) we calculated that between 81 and 162 patients (best/worst case scenario) would have been necessary to provide significant test results.</s><s>A post interventional increase of one dose level or more occurred in 20/26 (77%) subjects of active and in 9/14 (64%) subjects of placebo group who presented with objective signs both at baseline and post intervention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Skin prick test</head><p><s>Maximum histamine induced wheal diameter at baseline was 5.0 mm [Interquartile range/IQR</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory investigations</head><p><s>At baseline, sIgE-ab &gt; 0.35kU/l against Cor a 1, Dau c1, Mal d1, Pru av1 were detected in all subjects, against Api g 1 in 51/54, against soybean extract in 10/54, Bet v 2 in 5/54 and MUXF3 in 4/54.</s><s>Low level Gly m 5 and Gly m 6 sIgE was seen exclusively in one patient (0.52 and 0.99kU/l, respectively).</s></p><p><s>At baseline (t1), no relevant group differences were shown for any sIgE-ab investigated.</s><s>In neither group, courses of sIgE-ab showed significant differences from t1 to t5 for Bet v 1, Gly m 4 or any other allergen investigated.</s></p><p><s>In the active, but not in the placebo group, a significant increase from t1 to t5 for sIgG4-ab against Bet v 1 (figure <ref type="figure">4a,b</ref>), Gly m 4 (figure <ref type="figure">4c</ref>), Cor a 1 (figure <ref type="figure">4d</ref>), Api g 1 (p&lt;0.0001;</s><s>respectively), Dau c1 (p&lt;0.001),</s><s>Mal d 1 (p&gt;0.006)</s><s>and Pru av 1 (p&lt;0.015)</s><s>was found.</s><s>When comparing post interventional t5 values, there was a significant increase of sIgG4-ab against Gly m 4 (p=0.037)</s><s>and Cor a 1 (p=0.033)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p><p><s>in the active group; borderline significant increases occurred for sIgG4-ab against Bet v 1 (p=0.054),</s><s>Bet v 2 (p=0.074),</s><s>Pru av 1 (p=0.088)</s><s>and Mal d 1 (p=0.06).</s><s>No significant differences were seen for IgG4-ab against Gly m 5, Gly m 6, soybean extract, CCD, Api g1, Dau c 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality of life</head><p><s>FAQLQ-AF scores at baseline are given in table <ref type="table" target="#tab_2">1</ref>.</s><s>No significant differences between active and placebo group were found with nearly unchanged post interventional scores.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The BASALIT trial is the first randomized, double blind placebo controlled trial evaluating the efficacy of a component based birch pollen AIT on birch related soy FA in a multicentre setting.</s><s>The immunologic basis for this type of FA results from Bet v 1 homologous soy allergen Gly m 4 which shows 53% amino acid sequence identity and 63% sequence peptide similarity to Bet v 1 <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>.</s></p><p><s>Subjects with combined Bet v 1 and Gly m 4 sensitization were included.</s><s>Even though IgE values cannot safely predict reactivity at DBPCFC <ref type="bibr">[32,</ref><ref type="bibr">33]</ref> we initially decided to only include patients with defined IgE cut off values.</s><s>The rBet v 1-FV extract was chosen for AIT as it shows low IgE-binding <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr">34]</ref>, was well tolerated in higher doses with no increase in adverse effects compared with the native extract and induced a significant increase in birch pollen sIgG4-ab <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr">35]</ref>.</s></p><p><s>A main limiting factor for investigations on FA is the availability of standardized CM with standardized allergen content to be used within DBPCFC.</s><s>For this trial we set up standardized soy CM with consistent levels for protein contents and Gly m 4 levels <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>Also, a standardized evaluation system was established <ref type="bibr" target="#b23">[24]</ref>.</s><s>Despite of intensified efforts, we only reached 56% of the intended sample size within the given time frame.</s></p><p><s>The rBet v 1-FV extract was well tolerated and, as in previous trials <ref type="bibr" target="#b21">[22,</ref><ref type="bibr">35]</ref>, the safety profile was comparable with placebo; no rBet v 1-FV related severe adverse effects occurred.</s><s>Subjects of active group had received cumulative Bet v 1 allergen doses being eight to twenty fold higher compared with previous AIT studies on pollen related FA (i.e.</s><s>50µg <ref type="bibr" target="#b17">[18]</ref> and 150µg <ref type="bibr" target="#b11">[12]</ref>).</s></p><p><s>LOAEL obj at post interventional DBPCFC tended to be higher in active compared with placebo group in per protocol population.</s><s>In detail, at baseline DBPCFC objective signs occurred in 82% of active versus 78% of placebo group and at post interventional DBPCFC in only 23% versus 47%.</s><s>No significant differences were seen with regard to LOAEL subj or any overall occurrence of subjective symptoms between groups.</s><s>Possibly, effects could have been more pronounced by applying higher</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p><p><s>soy allergen doses, as only 80% of all subjects presented with objective signs at baseline DBPCFC.</s></p><p><s>Allergen doses were comparable to those having been reported in a previous trial, where, however, another food matrix had been applied <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>In the active group, some subjects showed post interventional decrease of LOAEL while, remarkably, in the placebo group, a LOAEL increase was not rare (figure <ref type="figure">3</ref>).</s><s>One might speculate that there is a fluctuating course of the pollen related FA being influenced not only by birch pollen season but also by other clinical cofactors that might not have been fully eliminated at some time points of DBPCFC.</s></p><p><s>In vitro investigations indicated an immunogenic effect of the rBet v 1-FV extract as there was a significant increase of Bet v 1 sIgG4-ab in active group which was more than twice as high as in previous trials using birch allergen extracts with lower Bet v 1 allergen levels <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>Despite a significant increase of sIgG4-ab to all Bet v 1 homologues investigated we noticed significant between-group effects only for sIgG4-ab against Gly m 4 and Cor a 1.</s><s>However, sIgG4-ab against Bet v 1, Bet v 2, Pru av 1 and Mal d 1 tended to be higher in rBet v 1-FV group.</s></p><p><s>In accordance with our data, an increase of sIgG4-ab against Bet v 1 and Cor a 1 was demonstrated in another trial investigating the effect of one year whole extract birch pollen-SCIT in birch related hazelnut allergy <ref type="bibr" target="#b18">[19]</ref>.</s><s>Even though sIgG4-ab were expected to be functionally blocking, authors failed to show clinical improvement of hazelnut allergy after one year of treatment <ref type="bibr" target="#b18">[19]</ref>.</s></p><p><s>In another recent trial, authors discussed that birch pollen-AIT may induce Bet v 1 sIgG4-ab that cross-react with related food allergens Mal d 1 and Cor a 1 and inhibit sIgE binding by epitope competition <ref type="bibr" target="#b11">[12]</ref>.</s><s>This effect was detectable after one year but was even stronger after three years of AIT (cumulative allergen dose 500µg) <ref type="bibr" target="#b11">[12]</ref>, and reduction in food allergen reactive sIgE-ab started only later than 12 months of AIT.</s><s>Interestingly, sIgG4-ab were not simply IgE epitope identical as more than 35% of predicted IgE epitopes of Bet v 1, Mal d 1 and Cor a 1 were not recognized by sIgG4-ab.</s><s>It was concluded that SCIT induced sIgG4-ab may not cover all IgE specificities <ref type="bibr" target="#b11">[12]</ref>.</s></p><p><s>Due to unexpected market withdrawal, the soy drink being scheduled for baseline and control SPT was only available in a subgroup of patients.</s><s>Therefore, we were not able to finally assess the influence of AIT on soy induced wheal diameter or on histamine adjusted wheal area <ref type="bibr" target="#b24">[25,</ref><ref type="bibr">36]</ref>.</s></p><p><s>Finally, in our trial, a rather small impact of birch related FA on QoL was measured which confirmed a previous single center experience <ref type="bibr">[29]</ref>.</s></p><p><s>In summary, for the first time we present data on the effect of AIT with the major birch pollen</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyrig</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Randomization (2:1) n=56 rBet v 1-FV n=38</head><p><s>Major protocol violation n=7</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PP population n=30</head><p><s>No start of therapy n=1</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Placebo n=18</head><p><s>Major protocol violation n=2</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PP population n=15</head><p><s>No start of therapy n=1</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>End of study (abnormal laboratory values, withdrawal of consent or other reasons) n=26</head><p><s>End of study (insufficient SPT/IgE-ab results, withdrawal of consent or other reasons) n=57)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Figure 1</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Figure 2</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="23,70.92,96.36,196.20,295.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="23,70.92,429.36,200.40,283.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 : Characteristics of randomized patients/ per protocol population</head><label>1</label><figDesc></figDesc><table><row><cell cols="3">BASALIT multicentre trial: Gly y m 4 quantification for consistency control of c</cell><cell>hallenge meal</cell></row><row><cell cols="3">batches and towards Gly m m 4 threshold data. Mol Nutr Food Res, 2016</cell><cell>Oct 17. doi:</cell></row><row><cell>10.1002/mnfr.201600527</cell><cell></cell><cell></cell></row><row><cell cols="4">27. Treudler R, Simon JC. Overvie ew of component resolved diagnostics. Curr Allergy y Asthma Rep.</cell></row><row><cell>2013 Feb;13(1):110-7.</cell><cell></cell><cell></cell></row><row><cell cols="4">28. Flokstra-de Blok BMJ, Van de er Meulen GN, DunnGalvin A, Vlieg-Boerstra BJ, O Oude Elberink</cell></row><row><cell cols="4">JN, Duiverman EJ et al. Dev velopment and validation of the Food Allergy Q Quality of Life</cell></row><row><cell cols="3">Questionnaire-Adult Form. Al llergy. 2009; 64: 1209-17</cell></row><row><cell cols="4">29. Beyer S, Franke A, Simon JC C, Treudler R. Measurement of health-related qu ality of life in</cell></row><row><cell cols="4">adult patients with birch po ollen associated food allergy. J Deutsch Derma atol Ges 2016</cell></row><row><cell>Apr;14(4):397-404</cell><cell></cell><cell></cell></row><row><cell cols="4">30. Bathke A, Brunner E. A Non nparametric Alternative to Analysis of Covariance e. In: Recent</cell></row><row><cell cols="2">Advances and Trends in No</cell><cell>nparametric Statistics. Eds. Akritas MG, Politis</cell><cell>DN. JAI Press</cell></row><row><cell cols="3">(Elsevier), Oxford, United King gdom, 2003; pp 109-120</cell></row><row><cell cols="4">31. Holm S. A simple sequentially y rejective multiple test procedure. Scand J Stat. 19 979;6:65-70</cell></row><row><cell cols="4">32. Celik-Bilgili S, Mehl A, Versteg ge A, Staden U, Nocon M, Beyer K et al. The pred ictive value of</cell></row><row><cell cols="4">specific immunoglobulin E lev vels in serum for the outcome of oral food challe enges. Clin Exp</cell></row><row><cell>Allergy 2005;35(3):268-73.</cell><cell></cell><cell></cell></row><row><cell cols="4">33. Husslik F, Nürnberg J, Seutter r von Loetzen C, Mews T, Ballmer-Weber BK, Klei ne-Tebbe J, et</cell></row><row><cell>al. The conformational IgE e</cell><cell cols="3">pitope profile of soya bean allergen Gly m 4. Cli in Exp Allergy.</cell></row><row><cell>2016 Nov;46(11):1484-1497</cell><cell></cell><cell></cell></row><row><cell cols="4">34. Husslik F, Hanschmann KM, K Krämer A, Seutter von Loetzen C, Schweimer K, Be ellinghausen I,</cell></row><row><cell cols="4">et al. Folded or Not? Trackin ng Bet v 1Conformation in Recombinant Allergen</cell><cell>Preparations.</cell></row><row><cell cols="3">PLoS One. 2015 Jul17;10(7):e0 0132956.</cell></row><row><cell cols="4">35. Klimek L, Bachert C, Lukat KF F, Pfaar O, Meyer H, Narkus A. Allergy immunot herapy with a</cell></row><row><cell cols="4">hypoallergenic recombinant b birch pollen allergen rBet v 1-FV in a randomized co ontrolled trial.</cell></row><row><cell cols="3">Clin Transl Allergy. 2015 Aug 3 3;5:28.</cell></row><row><cell cols="4">36. Dreborg S, Basomba A, Löfk kvist T, Holgersson M, Möller C. Evaluation of S Skin Reactivity</cell></row><row><cell>during (Immuno-) Therapy.</cell><cell></cell><cell cols="2">Validation of Methods for Estimation of Cha anges in Skin</cell></row><row><cell cols="3">Reactivity and Correlation to o Shock Organ Sensitivity. Immunother Open Acc</cell><cell>2016; 2: 109.</cell></row><row><cell>doi:10.4172/2471-9552.1000</cell><cell cols="2">109</cell></row><row><cell cols="3">ght. All rights reserved.</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 Active</head><label>2</label><figDesc></figDesc><table><row><cell>(rBet v 1-FV) group</cell><cell>Placebo group</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2 : Double blind placebo controlled food challenge (DBPCFC)-related outcome measures</head><label>2</label><figDesc><div><p><s>Data presented for both interventional groups (including primary endpoints) with median values [interquartile range] of lowest observed adverse effect levels for objective signs and subjective symptoms (LOAEL obj/subj ); no significant group differences after SCIT (* in per protocol population[PPP] between-group effect for treatment with p-value =0.081) were observed.</s></p></div></figDesc><table /></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p><p><s>allergen Bet v 1 on birch pollen related FA to soy.</s><s>This is the only study having investigated AIT induced changes in FA symptoms by means of standardized food challenge procedures and CM with consistent soy allergen levels <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>One year SCIT with rBet v 1-FV showed a clear immunogenic effect on sIgE-and sIgG4-ab against Bet v 1 and Bet v 1 homologous food allergens.</s><s>Clinical assessment showed a tendency in favor of the active group but did not reach statistical significance.</s></p><p><s>One reason may be that the treatment period was too short to induce changes on relevant antibody levels, on epitopes or on clinical symptoms.</s><s>Another reason lies in the fact that we failed to recruit the intended study sample size and, therefore, conclusive clinical results could not be reached.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Aknowledgement:</head><p><s>This trial was funded by the German Federal Ministry of Education and Research (FK 01KG0911).</s><s>Trial medication as well as skin prick test solutions were kindly supplied by Allergopharma GmbH &amp; Co. KG (Reinbek, Germany).</s><s>We thank Uelzena (Uelzen, Germany) for kindly providing Supro® soy protein, Dr. R. Frontini and J. Zimmer (Pharmacy of the University Hospital, Leipzig, Germany) for production and Dr. rer.</s><s>nat. A. Willenberg (Institute of laboratory medicine, Clinical chemistry and Molecular diagnostics, University Hospital, Leipzig, Germany) for microbiological investigations of challenge meals, the ZKS (Leipzig, Germany) for study logistics, data management, monitoring and biometry as well as B. Flokstra-de Blok (Groningen, The Netherlands) for kindly providing FAQL-questionnaire.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions:</head><p><s>RT, AF, AS, JCS generated the concept of the study including set up of challenge meal and defined standardized procedures for DBPCFC; SV, MW, TW, JKT, BBW gave advice to DBPCFC and preparation of challenge meal; TH did analysis of Gly m 4 levels in challenge meals and organised and supervised sIgE and sIgG4; RT, JCS, MW, TB, TW, UJ, BBW, RB, AK, JS, HB, JKT, FR, JR, JS, KS recruited patients for DBPCFC and SCIT.</s><s>All authors revised and approved the manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflicts of interest:</head><p><s>RT report unrestricted research grant from ALK-Abello, fees for lectures and advisory boards from ALK-Abello, Novartis, fees for lectures from Meda, Shire, travel grants from Shire, all outside the submitted work.</s><s>AF and AS report a grant from Funding Program for clinical trials of German Ministry for education and research (BMBF), BMBF/ DLR Funding-ID 01 KG 0911, for conduct of the study but</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Accepted Article</head><p><s>This article is protected by copyright.</s><s>All rights reserved.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Clinical characterization and IgE profiling of birch (Betula verrucosa)-allergic individuals suffering from allergic reactions to raw fruits and vegetables</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tolkki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Alanko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Petman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Skydtsgaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Milvang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Seppälä</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol Pract</title>
		<imprint>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="623" to="631" />
			<date type="published" when="2013-11">2013 Nov-Dec;1</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">High risk of immediate-type reactions to soy drinks in 50 patients with birch pollinosis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Treudler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thiery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kramer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gebhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Averbeck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Investig Allergol Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="483" to="484" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Soy allergy in perspective</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Ballmer-Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vieths</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="270" to="275" />
			<date type="published" when="2008-06">2008 Jun</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Clinical characteristics of soybean allergy in Europe: a double-blind, placebo-controlled food challenge study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Ballmer-Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Holzhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Scibilia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mittag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ortolani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1489" to="1496" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for crossreactivity with Bet v 1-related food allergens</title>
		<author>
			<persName><forename type="first">B</forename><surname>Jahn-Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Radakovics</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lüttkopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Scheurer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vieths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ebner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="213" to="219" />
			<date type="published" when="2005-07">2005 Jul</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1-related PR-10 protein in soybean, SAM22</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kleine-Tebbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Crowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">F</forename><surname>Haustein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vieths</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="797" to="804" />
			<date type="published" when="2002-11">2002 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens</title>
		<author>
			<persName><forename type="first">D</forename><surname>Mittag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vieths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Rihs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="148" to="154" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Acute and long-term management of food allergy: systematic review</title>
		<author>
			<persName><forename type="first">D</forename><surname>De Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Geromi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Panesar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Werfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hoffmann-Sommergruber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens</title>
		<author>
			<persName><forename type="first">T</forename><surname>Werfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Ballmer-Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Enrique</forename><forename type="middle">E</forename><surname>Knulst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1079" to="1090" />
			<date type="published" when="2015-09">2015 Sep</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">German Dermatological Society (DDG), the German Society for Nutrition (DGE), the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS), the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery, the German Society for Pediatric and Adolescent Medicine (DGKJ), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Society for Pneumology (DGP), the German Society for Pediatric Gastroenterology and Nutrition (GPGE)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Reese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ballmer-Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bischof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Claßen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">German Contact Allergy Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), German Professional Association of Nutritional Sciences (VDOE) and the Association of the Scientific Medical Societies Germany (AWMF)</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="256" to="293" />
		</imprint>
	</monogr>
	<note>S2k-Guidelines of the German Society for Allergology and Clinical Immunology ( DGAKI) in collaboration with the German Medical Association of Allergologists (AeDA), the German Professional Association of Pediatricians (BVKJ), the German Allergy and Asthma Association (DAAB)</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Severe soy allergy in adults. Is there a role for specific immunotherapy?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Treudler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Simon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hautarzt</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="307" to="312" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Reider Net al. Kinetics, crossreactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen</title>
		<author>
			<persName><forename type="first">B</forename><surname>Subbarayal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schiller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Möbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ebner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1377" to="1386" />
			<date type="published" when="2013-11">2013 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Effects of birch pollen-specific immunotherapy on apple allergy in birch pollenhypersensitive patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1368" to="1373" />
			<date type="published" when="1998-11">1998 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Bolhaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Tiemessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zuidmeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hoffmann-Sommergruber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Bruijnzeel-Koomen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Allergy</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="761" to="769" />
			<date type="published" when="2004">2004May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut</title>
		<author>
			<persName><forename type="first">X</forename><surname>Bucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Pichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Helbling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Birch-apple syndrome treated with birch pollen immunotherapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Russello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Incorvaia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gazzola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Frati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moingeon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="416" to="422" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Effect of pollen-specific sublingual immunotherapy on oral allergy syndrome: an observational study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Bergmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schnitker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Allergy Organ J</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="79" to="84" />
			<date type="published" when="2008-05">2008 May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Food allergy to apple and specific immunotherapy with birch pollen</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><surname>Ms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Skov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bindslev-Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Poulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Malling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Nutr Food Res</title>
		<imprint>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Van Hoffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Peeters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Van Neerven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Van Der Tas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zuidmeer</surname></persName>
		</author>
		<author>
			<persName><surname>Vanieperen-Van</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="e1" to="3" />
			<date type="published" when="2011-01">2011 Jan</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kinaciyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jahn-Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Radakovics</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zwölfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Francis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Allergy Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="937" to="943" />
			<date type="published" when="2007-04">2007 Apr</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Effects of birch pollen SIT on apple allergy: a matter of dosage?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Asero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1269" to="1271" />
			<date type="published" when="2004-12">2004 Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber</title>
		<author>
			<persName><forename type="first">W</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Narkus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Salapatek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Häfner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="724" to="731" />
			<date type="published" when="2013-06">2013 Jun</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kahlert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Suck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nandy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Keller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="193" to="206" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Standardization of double blind placebo controlled food challenge with soy within a mulicentri trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Treudler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Franke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmiedeknecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Ballmer-Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Worm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Werfel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Allergy</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">39</biblScope>
			<date type="published" when="2016-11-07">2016 Nov 7</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Allergen skin prick test should be adjusted by the histamine reactivity</title>
		<author>
			<persName><forename type="first">S</forename><surname>Dreborg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Arch Allergy Immunol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="77" to="80" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Holzhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Franke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Treudler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schmiedeknecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Randow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Becker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Age</title>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
